DDInter905 DDInter1341
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth
Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. SMA is a rare genetic disease that affects the survival and function of motor neurons, leading to debilitating and often fatal muscle weakness. As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms. The use and effectiveness of onasemnogene abeparvovec in patients with advanced SMA, such as those with complete paralysis of the limbs and permanent dependence on ventilators, has not been evaluated. Onasemnogene abeparvovec is the first gene therapy that was approved for this indication in the USA. [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients. Developed by AveXis, a Novartis company, onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion. Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA.
Idelalisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Idelalisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eltrombopag
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Idelalisib {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Idelalisib {u} may lead to a major life threatening interaction when taken with {v} Vinorelbine
Idelalisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Idelalisib may lead to a major life threatening interaction when taken with Vinorelbine